Research graph
References from Clinical features and treatment strategies of immune checkpoint inhibitor- related thyroid dysfunction in patients with biliary and ampullary malignancies. Local targets link to admitted publications; unresolved targets remain external evidence.
Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens:a systematic review and meta-analysis [J]
10.1001/jamaoncol.2017.3064 · 2018 · External reference
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management [J]
10.1016/j.ctrv.2017.06.002 · 2017 · External reference
Expert consensus on endocrine immune-related adverse events induced by immune checkpoint inhibitors (2020) [J]
2021 · External reference
Thyroid disorders induced by immune checkpoint inhibitors [J]
10.1007/s12020-024-03718-2 · 2024 · External reference
Autoimmune thyroid disease elicited by NY-ES0-1 vaccination [J]
10.1089/thy.2013.0170 · 2014 · External reference
Unresolved reference
2021 · External reference
10.1016/s0140-6736(13)61903-0
10.1016/s0140-6736(13)61903-0 · 2014 · External reference
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer [J]
2022 · External reference
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial [J]
10.1016/s0140-6736(23)00727-4 · 2023 · External reference
The future of immune checkpoint therapy[J].2015
External reference
New insight inendocrine-related adverse events associated to immune checkpoint blockade
10.1016/j.beem.2019.101370 · 2020 · External reference
Adverse effects of immune–checkpoint inhibitors: epidemiology, management and surveillance [J]
10.1038/s41571-019-0218-0 · External reference
Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan
External reference
Histology of nivolumab-induced thyroiditis [Jl
10.1089/thy.2018.0418 · 2018 · External reference
Endocrine toxicitys immune checkpoints of immunotherapy targeting cancer [J]
External reference
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
10.1172/jci80011 · 2015 · External reference
Autoantibody development under treatment with immune-checkpoint inhibitors [J]
10.1158/2326-6066.cir-18-0245 · 2019 · External reference
Thyroid function abnormalities associated with nivolumab treatment in patients with advanced solid tumors
2016 · External reference
Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade
2020 · External reference
Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal
2020 · External reference
Predictive value of thyroid peroxidase antibody for immune-related thyroid dysfunction in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
2021 · External reference
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
10.6004/jnccn.2020.0012 · 2020 · External reference
Endocrine toxicity of cancer immunotherapy targeting immune checkpoints [J]
External reference
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group [J]
10.1186/s40425-017-0300-z · 2017 · External reference
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline [J]
10.1200/jco.2017.77.6385 · 2018 · External reference
Immune–related adverse events and anti–tumor efficacy of immune checkpoint inhibitors [J]
10.1186/s40425-019-0805-8 · 2019 · External reference
